This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Arteaga-Pérez, M. E Articles by Cedeño, M Search for Related Content PubMed PubMed Citation Articles by Arteaga-Pérez, M. E Articles by Cedeño, M Social Bookmarking                         What's this?

Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

Centro Nacional para la Producción de Animales de Laboratorio (CENPALAB), Habana, Cuba

M Maceira

Centro de Inmunología Molecular (CIM), Habana, Cuba

A Casaó

Centro de Inmunología Molecular (CIM), Habana, Cuba; Division of Immuno pharmacology, Center of Molecular Immunology, 216 Esq. a 15, Siboney, Playa, A. Postal 16040, Habana 11600, Cubacasaco{at}ict.cim.sld.cu

O Hernández-Sosa

Ana M Bada-Barro

A León-Goñí

R Orpheé-Suárez

A Cuevas-Fiallo

D Moreno-Díaz

Centro Nacional para la Producción de Animales de Laboratorio (CENPALAB), Habana, Cuba

P Padro-Gutiérrez

F Baro-González

V Rodríguez-Rodríguez

L Charoo-Ruiz

Centro de Neurociencias, Centro Nacional de Investigaciones Científicas (CNIC), Habana, Cuba

F Vázquez-Castro

Centro de Investigaciones Médico Quirúrgicas (CIMEQ), Habana, Cuba

A Ballester-Labrada

Centro de Investigaciones Clínicas (CIC), Habana, Cuba

M Cedeño

Centro de Inmunología Molecular (CIM), Habana, Cuba

The h-R3 is a humanized growth factor receptor monoclonal antibody (mAb) in development for the treatment of head and neck tumours in which malignant cells overexpress the Epidermal Growth Factor receptor. The present study was designed to evaluate the toxicity of repeated intravenous doses of the h-R3 mAb in a relevant species demonstrated by the avidin-biotin-peroxidase immunohistochemical (IHC) technique in skin biopsy samples from three Cercopithecus aethiops sabaeus monkeys (green monkeys). Additionally, 18 green monkeys were daily intravenously treated during 14 consecutive days. Monkeys were distributed into three experimental groups with three animals of each sex in each group. Group I received saline solution and served as control group; group II received 2.85 mg/kg of h-R3 mAb; and group III received 11.4 mg/kg of the h-R3 mAb. During the study there were no deaths, neither pathological clinical signs, or variations in the corporal weight curve. The electroneurophysiological and sanguine chemistry results did not evidence alterations related to the assay substance. Areas of haematomas, haemorrhages and inflammation, probably related with the administration procedure, were observed at the administration zones of all animals; this fact could also explain the increase in the neutrophil count of all animals at the end of the study. The electrocardiography study showed that in the 14 days of the study one female monkey, from the higher dose group, shifted its cardiac axis from +60° to +120°; this finding could be interpreted as a right ventricular elongation due to the relative high daily administered volume.

It is concluded that doses up to 11.4 mg/kg of h-R3, intravenously administered during 14 consecutive days to Cercopithecus aethiops sabaeus monkeys do not produce considerable toxic effects in the studied system.

Key Words: cancer treatment • h-R3 • monoclonal antibody • nonhuman primates • toxicity

Human & Experimental Toxicology, Vol. 23, No. 5, 219-227 (2004)
DOI: 10.1191/0960327104ht438oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Talavera, R. Friemann, S. Gomez-Puerta, C. Martinez-Fleites, G. Garrido, A. Rabasa, A. Lopez-Requena, A. Pupo, R. F. Johansen, O. Sanchez, et al. Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation Cancer Res., July 15, 2009; 69(14): 5851 - 5859. [Abstract] [Full Text] [PDF]